Quantcast

Latest OncoGenex Pharmaceuticals Inc. Stories

2011-06-28 07:00:00

BOTHELL, WA and VANCOUVER, British Columbia, June 28, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients, announced today that the Company was added to the Russell Global Index, Russell 2000® Index, Russell 3000® Index and Russell Microcap® Index at the close of...

2011-06-06 07:00:00

BOTHELL, Wash. and VANCOUVER, British Columbia, June 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced new data showing how the company's lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors to suppress prostate cancer cell survival and improve treatment outcomes. These pre-clinical data were presented at the 47th Annual Meeting of the American Society of Clinical...

2011-05-17 07:00:00

BOTHELL, WA, and VANCOUVER, May 17 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Cameron Lawrence, OncoGenex' Director of Finance and Principal Accounting Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Wednesday, May 25 at 10:00 a.m. BST (5:00 a.m. ET). The conference takes place at the UBS offices in London. The live audio webcast can be accessed through the Investor Relations page of the OncoGenex website...

2011-05-09 15:00:00

BOTHELL, WA and VANCOUVER, BC, May 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter financial results and provided an update on current events and activities. Key OncoGenex Activities -- Currently enrolling the Phase 3 clinical trial referred to as SYNERGY, to be conducted in approximately 123 cancer centers to evaluate a survival benefit for custirsen in combination with...

2011-05-02 07:00:00

BOTHELL, WA and VANCOUVER, May 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's first quarter 2011 financial results will be released on Monday, May 9, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business. To access the webcast, log...

2011-04-14 07:00:00

BOTHELL, Wash. and VANCOUVER, British Columbia, April 14, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the European Patent Office (EPO) has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers." The patent, licensed from The University of British Columbia, includes coverage for antisense and siRNA compositions that reduce the amount of active Heat Shock Protein 27 (Hsp27) in Hsp27...

2011-04-04 12:00:00

BOTHELL, Wash. and VANCOUVER, British Columbia, April 4, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011. The study demonstrated the ability of OGX-427 to inhibit Heat Shock Protein 27 (Hsp27), a cell-survival protein believed to play an important role in the proliferation of castrate resistant prostate cancer (CRPC) and resistance to...

2011-03-29 07:00:00

BOTHELL, WA and VANCOUVER, BC, March 29 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex' president and chief executive officer, will provide a corporate presentation at the Needham & Company 10(th) Annual Healthcare Conference on Wednesday, April 6 at 2:40 p.m. ET. The corporate presentation will be webcast live and can be accessed through the Investor Relations page of the OncoGenex website at...

2011-03-10 15:01:00

BOTHELL, WA and VANCOUVER, March 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its fourth quarter and year end 2010 financial results, reviewed updates to the Company's development programs and provided an outlook for 2011. "Over the course of the last twelve months we've delivered on our corporate objectives to initiate two Phase 3 clinical trials evaluating custirsen in castrate-resistant prostate cancer and a randomized Phase 2...

2011-03-07 05:00:00

BOTHELL, WA and VANCOUVER, March 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and full year 2010 financial results will be released on Thursday, March 10, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide a 2011 corporate outlook....


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related